Zynerba Pharmaceuticals, Inc.
TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL

Abstract:

The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.